Straits Times Index
3,256.93 +31.76 (+0.98%) Nikkei
37,535.27 +96.66 (+0.26%) Hang Seng
16,784.30 +272.61 (+1.65%) FTSE 100
8,023.87 +128.02 (+1.62%) Bitcoin USD
66,552.30 +280.84 (+0.42%) CMC Crypto 200
1,402.32 -12.44 (-0.88%)
Rocket Pharmaceuticals, Inc. (RCKT)
After hours:
| Previous close | 22.80 |
| Open | 23.00 |
| Bid | 23.85 x 200 |
| Ask | 23.99 x 100 |
| Day's range | 22.79 - 24.20 |
| 52-week range | 14.89 - 32.53 |
| Volume | |
| Avg. volume | 716,362 |
| Market cap | 2.16B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.92 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.33 |
ZacksEMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
Business WireRocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
CRANBURY, N.J., April 02, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102, its lentiviral (LV) vector-based investigational gene therapy for Fanconi Anemia (FA), complementation group A, a rare genetic disorder caused by muta
ZacksWhy Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
